|
시장보고서
상품코드
1812434
세계의 폐암 시장 : 유형별, 약제 클래스별, 분자 유형별, 투여 경로별, 병기별, 연령층별, 성별, 유통 채널별, 최종 사용자별, 지역별Lung Cancer Market, By Type, By Drug Class, By Molecule Type, By Route of Administration, By Stage of Disease, By Age Group, By Gender, By Distribution Channel, By End User, By Geography |
||||||
세계의 폐암 시장은 2025년 281억 2,000만 달러로 추정되고, 2023년까지 645억 3,000만 달러에 이를 전망으로, 2025년부터 2032년까지 연평균 성장률(CAGR) 12.6%로 성장이 예측되고 있습니다.
| 보고 범위 | 보고서 세부정보 | ||
|---|---|---|---|
| 기준연도 | 2024년 | 2025년 시장 규모 | 281억 2,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2020-2024년 |
| 예측기간 : 2025-2032년 CAGR : | 12.60% | 2032년 가치 예측 | 645억 3,000만 달러 |
세계의 폐암 시장은 암 치료제 중 가장 중요한 분야 중 하나이며, 암 관련 사망의 주요 원인인 폐암이라는 세계적으로 뿌리 깊은 과제에 의해 견인되고 있습니다. 이 악성 종양은 연간 수백만 명의 환자를 앓고 있으며, 비소세포폐암(NSCLC)이 전 증례의 약 85%를 차지하고 소세포폐암(SCLC)이 남은 15%를 차지하고 있습니다. 이 시장은 진단 도구 및 지원 요법 외에도 화학 요법, 표적 요법, 면역 요법, 방사선 요법, 수술 등 종합적인 치료 중재를 포함합니다.
흡연 습관, 환경 오염물질, 직업적 위험, 유전적 소인으로 인한 유병률의 상승이 세계적인 수요를 부추기고 있습니다. 바이오마커 주도형 치료, 면역관문 억제제, 티로신 키나아제 억제제와 같은 정밀의료 접근법의 도입으로 치료 환경은 획기적인 진보를 이루었고 환자 결과는 크게 개선되었습니다. 의료 인프라의 정비, 조기 발견 프로그램에 대한 의식의 높아짐, 제약 기업에 의한 연구개발 활동에의 다액의 투자가, 총체적으로 시장의 궤도를 형성하고 있습니다.
시장 역학
세계의 폐암 시장은 그 강력한 성장 궤도에 총체적으로 기여하는 여러 가지 촉진요인이 있으며, 동시에 확대율을 완만하게 하는 한편, 미래 시장 개척에 큰 기회를 가져다주는 특정 제약 요인에도 직면하고 있습니다. 주요 시장 성장 촉진요인으로는 담배 소비량 증가, 대기 오염, 발암 물질에 대한 직업적 노출, 유전적 감수성 등에 의한 폐암 이환율의 세계적인 상승을 들 수 있으며, 이들은 치료적 개입을 필요로 하는 환자 집단을 총체적으로 확대하고 있습니다.
면역요법, 특히 PD-1/PD-L1 억제제와 같은 면역관문 억제제의 획기적인 진보는 치료 패러다임을 변화시켜 큰 시장 기회를 창출했습니다. 한편, EGFR, ALK, ROS1과 같은 특정 유전자 돌연변이에 초점을 맞춘 표적 치료법의 개발은 탁월한 효능을 나타내는 맞춤 치료 접근법을 가능하게 했습니다. 신흥국의 의료 인프라 개선, 의료비 증가, 스크리닝 프로그램에 의한 조기 진단에 대한 의식이 높아짐에 따라 시장 성장이 더욱 가속화되고 있습니다.
그러나 혁신적인 암 치료와 관련된 비용이 매우 높고, 특히 신흥국 지역에서의 접근이 제한되는 것, 의약품 승인까지의 기간을 장기화시키는 엄격한 규제 프레임워크, 불확실한 결과를 수반하는 다액의 투자를 필요로 하는 의약품 개발 프로세스의 복잡한 성질 등, 시장 확대는 큰 억제요인에 직면하고 있습니다.
블록버스터 의약품의 특허 만료은 기존 기업에게 가격 압력과 시장 점유율 저하를 초래합니다. 그럼에도 불구하고 치료 효과를 높이는 병용 요법 개발, 미개척 지역 시장 진출, 맞춤형 의료를 위한 동반진단의 진보, 진단과 치료 선택 개선을 위한 인공지능과 머신러닝 기술의 통합 등을 통해 큰 비즈니스 기회가 존재합니다. 조기 암 치료에 대한 관심 증가, 새로운 약물 전달 시스템의 개발, 제약 기업과 연구 기관의 공동 연구 증가는 시장 확대와 기술 혁신의 또 다른 길을 보여줍니다.
본 조사의 주요 특징
- 본 보고서에서는 세계의 폐암 시장을 상세하게 분석하여 2024년을 기준연도로 한 예측기간(2025-2032년) 시장 규모(10억 달러) 및 복합 연간 성장률(CAGR%)을 제공합니다.
- 또한 다양한 부문에서 잠재적인 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 행렬에 대해 설명합니다.
- 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채용하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 매개변수를 바탕으로 세계 폐암 시장의 주요 기업을 프로파일링하고 있습니다.
- 이 보고서의 통찰을 통해 마케팅 담당자와 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전술에 대한 정보를 바탕으로 의사 결정을 내릴 수 있습니다.
- 세계 폐암 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 업계의 다양한 이해관계자를 지원합니다.
- 이해관계자는 세계의 폐암 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 출시/승인
- PEST 분석
- Porter's Five Forces 분석
- 합병과 인수 시나리오
- 업계 동향
제4장 세계의 폐암 시장, 유형별, 2020-2032년
- 비소세포폐암(NSCLC)
- 소세포 폐암(SCLC)
- 폐카르티노이드 종양
제5장 세계의 폐암 시장, 약제 클래스별, 2020-2032년
- 세포독성 화학요법
- 표적요법
- 면역요법
- 기타
제6장 세계의 폐암 시장, 분자 유형별, 2020-2032년
- 저분자
- 생물학적 제형
제7장 세계의 폐암 시장, 투여 경로별, 2025-2032년
- 비경구
- 경구
제8장 세계의 폐암 시장, 병기별, 2020-2032년
- 조기암(I-II단계)
- 국소 진행암(III단계)
- 전이성 및 진행성 암(IV단계)
제9장 세계의 폐암 시장, 연령층별, 2020-2032년
- 성인
- 소아
- 고령자
제10장 세계의 폐암 시장, 성별, 2020-2032년
- 남성
- 여성
제11장 세계의 폐암 시장, 유통 채널별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 폐암 시장, 최종 사용자별, 2020-2032년
- 병원
- 진단 실험실
- 전문암 클리닉
- 재택치료
- 기타(연구 및 학술 기관 등)
제13장 세계의 폐암 시장, 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙 아프리카
제14장 경쟁 구도
- Hoffmann-La Roche Ltd.
- Novartis AG
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck and Co., Inc.(MSD)
- Pfizer Inc.
- Eli Lilly and Company
- Johnson and Johnson(Janssen Biotech, Inc.)
- Amgen Inc.
- AbbVie Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Daiichi Sankyo Company, Limited
- Astellas Pharma Inc.
- Regeneron Pharmaceuticals, Inc.
제15장 분석가 추천
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제16장 참고문헌과 조사방법
- 참고문헌
- 조사 방법
- 출판사에 대해
Lung Cancer Market is estimated to be valued at USD 28.12 Bn in 2025 and is expected to reach USD 64.53 Bn by 2032, growing at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 28.12 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 12.60% | 2032 Value Projection: | USD 64.53 Bn |
The global lung cancer market represents one of the most critical segments within the oncology therapeutics landscape, driven by the persistent challenge of lung cancer as the leading cause of cancer-related mortality worldwide. This malignancy affects millions of patients annually, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all cases, while small cell lung cancer (SCLC) comprises the remaining 15%. The market encompasses a comprehensive spectrum of therapeutic interventions including chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, alongside diagnostic tools and supportive care solutions.
Rising prevalence rates attributed to smoking habits, environmental pollutants, occupational hazards, and genetic predispositions continue to fuel demand globally. The therapeutic landscape has witnessed revolutionary advancements through the introduction of precision medicine approaches, including biomarker-driven treatments, immune checkpoint inhibitors, and tyrosine kinase inhibitors that have significantly improved patient outcomes. Healthcare infrastructure development, increasing awareness about early detection programs, and substantial investments in research and development activities by pharmaceutical companies are collectively shaping the market trajectory.
Market Dynamics
The global lung cancer market is propelled by multiple driving factors that collectively contribute to its robust growth trajectory, while simultaneously facing certain constraints that moderate expansion rates, yet presenting significant opportunities for future development. Primary market drivers include the escalating global incidence of lung cancer due to increasing tobacco consumption, air pollution, occupational exposure to carcinogens, and genetic susceptibilities, which collectively expand the patient population requiring therapeutic interventions.
The revolutionary advancement in immunotherapy treatments, particularly immune checkpoint inhibitors such as PD-1/PD-L1 inhibitors, has transformed treatment paradigms and created substantial market opportunities, while targeted therapy developments focusing on specific genetic mutations like EGFR, ALK, and ROS1 have enabled personalized treatment approaches that demonstrate superior efficacy rates. Healthcare infrastructure improvements in emerging economies, coupled with increasing healthcare expenditure and growing awareness about early diagnosis through screening programs, further accelerate the market growth.
However, market expansion faces significant restraints including the extremely high costs associated with innovative cancer treatments, which limit accessibility particularly in developing regions, stringent regulatory frameworks that prolong drug approval timelines, and the complex nature of drug development processes that require substantial investments with uncertain outcomes.
Patent expiration of blockbuster drugs creates pricing pressures and market share erosion for established players. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance treatment efficacy, expansion into untapped geographical markets, advancement in companion diagnostics for personalized medicine, and the integration of artificial intelligence and machine learning technologies for improved diagnosis and treatment selection. The growing focus on early-stage cancer treatment, development of novel drug delivery systems, and increasing collaborations between pharmaceutical companies and research institutions present additional avenues for market expansion and innovation.
Key Features of the Study
- This report provides in-depth analysis of the global lung cancer market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca plc, Bristol Myers Squibb Company, Merck and Co., Inc. (MSD), Pfizer Inc., Eli Lilly and Company, Johnson and Johnson (Janssen Biotech, Inc.), Amgen Inc., AbbVie Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, Astellas Pharma Inc., and Regeneron Pharmaceuticals, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lung cancer market.
Market Segmentation
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Non-Small Cell Lung Cancer (NSCLC)
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Small Cell Lung Cancer (SCLC)
- Lung Carcinoid Tumor
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Cytotoxic Chemotherapy
- Alkylating agents (cisplatin, carboplatin, etc.)
- Antimetabolites (pemetrexed, gemcitabine)
- Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
- Topoisomerase inhibitors (etoposide, irinotecan)
- Others
- Targeted Therapy
- EGFR Inhibitors (Erlotinib, etc.)
- ALK Inhibitors (Crizotinib, etc.)
- ROS1 Inhibitors (Entrectinib, etc.)
- BRAF/MEK Inhibitors (Dabrafenib, etc.)
- MET Inhibitors (Capmatinib, etc.)
- RET Inhibitors (Selpercatinib, etc.)
- HER2 Inhibitors (Trastuzumab, etc.)
- Immunotherapy
- PD-1 Inhibitors (Nivolumab, etc.)
- PD-L1 Inhibitors (Atezolizumab, etc.)
- CTLA-4 Inhibitors (Ipilimumab, etc.)
- Other Combination Therapeutics
- Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small Molecules
- Biologics
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Parenteral
- Oral
- Stage of Disease Insights (Revenue, USD Bn, 2020 - 2032)
- Early-stage (Stage I-II)
- Locally Advanced (Stage III)
- Metastatic/Advanced (Stage IV)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Adult
- Pediatric
- Geriatric
- Gender Insights (Revenue, USD Bn, 2020 - 2032)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Diagnostic Laboratories
- Specialty Cancer Clinics
- Homecare Settings
- Others (Research and Academic Institutes, etc.)
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Hoffmann-La Roche Ltd.
- Novartis AG
- AstraZeneca plc
- Bristol Myers Squibb Company
- Merck and Co., Inc. (MSD)
- Pfizer Inc.
- Eli Lilly and Company
- Johnson and Johnson (Janssen Biotech, Inc.)
- Amgen Inc.
- AbbVie Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Daiichi Sankyo Company, Limited
- Astellas Pharma Inc.
- Regeneron Pharmaceuticals, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Lung Cancer Market, By Type
- Global Lung Cancer Market, By Drug Class
- Global Lung Cancer Market, By Molecule Type
- Global Lung Cancer Market, By Route of Administration
- Global Lung Cancer Market, By Stage of Disease
- Global Lung Cancer Market, By Age Group
- Global Lung Cancer Market, By Gender
- Global Lung Cancer Market, By Distribution Channel
- Global Lung Cancer Market, By End User
- Global Lung Cancer Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Lung Cancer Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Non-Small Cell Lung Cancer (NSCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adenocarcinoma
- Squamous Cell Carcinoma
- Large Cell Carcinoma
- Small Cell Lung Cancer (SCLC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Lung Carcinoid Tumor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Lung Cancer Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Cytotoxic Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alkylating agents (cisplatin, carboplatin, etc.)
- Antimetabolites (pemetrexed, gemcitabine)
- Mitotic inhibitors (taxanes: paclitaxel, docetaxel)
- Topoisomerase inhibitors (etoposide, irinotecan)
- Others
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- EGFR Inhibitors (Erlotinib, etc.)
- ALK Inhibitors (Crizotinib, etc.)
- ROS1 Inhibitors (Entrectinib, etc.)
- BRAF/MEK Inhibitors (Dabrafenib, etc.)
- MET Inhibitors (Capmatinib, etc.)
- RET Inhibitors (Selpercatinib, etc.)
- HER2 Inhibitors (Trastuzumab, etc.)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- PD-1 Inhibitors (Nivolumab, etc.)
- PD-L1 Inhibitors (Atezolizumab, etc.)
- CTLA-4 Inhibitors (Ipilimumab, etc.)
- Other Combination Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Lung Cancer Market, By Molecule Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Lung Cancer Market, By Route of Administration, 2025-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Lung Cancer Market, By Stage of Disease, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Early-stage (Stage I-II)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Locally Advanced (Stage III)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metastatic/Advanced (Stage IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Lung Cancer Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Lung Cancer Market, By Gender, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Lung Cancer Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Lung Cancer Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Cancer Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (Research and Academic Institutes, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Lung Cancer Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Stage of Disease, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Gender, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck and Co., Inc. (MSD)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson (Janssen Biotech, Inc.)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo Company, Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
